Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation

Leuk Lymphoma. 2007 Oct;48(10):2054-7. doi: 10.1080/10428190701549570.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / pharmacology*
  • Benzamides
  • Cell Line, Tumor
  • Chimerism
  • Cord Blood Stem Cell Transplantation / methods*
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Imatinib Mesylate
  • Piperazines / pharmacology*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / pharmacology*
  • Recurrence
  • Remission Induction
  • Thiazoles / pharmacology*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Dasatinib